# Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

> **NCT05518838** · — · NO_LONGER_AVAILABLE · sponsor: **Oblato, Inc.**

## Conditions studied

- Diffuse Midline Glioma, H3 K27M-Mutant
- Diffuse Intrinsic Pontine Glioma

## Interventions

- **DRUG:** OKN-007

## Key facts

- **NCT ID:** NCT05518838
- **Lead sponsor:** Oblato, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05518838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05518838, "Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05518838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*